Christophe Willekens

Author

Institut Gustave Roussy ORCID

Also Known As

C Willekens, C. Willekens, Christophe Willekens, WILLEKENS, Christophe, Willekens, Christophe

120

Publications

6.4K

Citations

H-Index

Concepts

All Affiliations

Institut Gustave Roussy Inserm Université Paris-Saclay Université Paris Cité Assistance Publique – Hôpitaux de Paris

About

Christophe Willekens is an author at Institut Gustave Roussy specializing in medicine, immunology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1.8K
2	Immunology	9	9	1.4K
3	Pathology	7	7	1.3K
4	Health Sciences	3	3	267
5	Cell Biology	1	1	93

Christophe Willekens

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Blood	2017	1.4K
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, New England Journal of Medicine	2018	1.4K
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 Aymeric Silvin, Nicolas Chapuis, Garett Dunsmore, Cell Mild Covid-19Hematological MalignancyHematologyImmunologyPathology	2020	898
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia Tamara Maes, Cristina Mascaró, Iñigo Tirapu, Cancer Cell Hematological MalignancyMedicineDrug DiscoveryMalignant Blood DisorderPharmacotherapy	2018	326
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia Dorothée Selimoglu‐Buet, Orianne Wagner‐Ballon, Véronique Saada, Blood	2015	249
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib Lynn Quek, Muriel D. David, Alison Kennedy, Nature Medicine Hematological MalignancyClonal HeterogeneityMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia	2018	193
Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers François‐Xavier Danlos, Claudia Grajeda‐Iglesias, Sylvère Durand, Cell Death and Disease	2021	161
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort Laurence Albigès, Stéphanie Foulon, Arnaud Bayle, Nature Cancer	2020	117
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial Christophe Willekens, Odile Blanchet, Aline Renneville, Haematologica	2015	109
First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia Olga Salamero, Pau Montesinos, Christophe Willekens, Journal of Clinical Oncology	2020	101

Page 1